ABLATE versus PACE: Pacemaker strategy reduces clinically relevant events in older patients with persistent atrial fibrillation Randomised trial shows substantially fewer hospitalisations and repeat interventions than pulmonary vein isolation. The benefit was partly offset by more heart failure events and ...

Prof. Jens Cosedis Nielsen discusses the DANISH-CRT trial, why targeted electrical mapping did not improve outcomes, and the questions that remain around the future of cardiac resynchronization therapy.

At EHRA 2026, Professor Claudio Tondo presents his highlights on advances in ablation and device technologies, led by pulsed field ablation, showcasing a rapidly evolving landscape in the treatment of complex arrhythmias.

Ventricular fibrillation (VF) is characterized by rapid (>300 beats a per minute), irregular electrical activation with variable electrocardiographic waveforms that prevents coordinated myocardial contraction, resulting in immediate loss of cardiac output.1 It most commonly occurs in the context of coronary ...

At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.

From EHRA 2026, Dr Salik Ur Rehman discusses advances in pulsed field ablation, mapping technologies, and conduction system pacing highlight a rapidly evolving landscape in electrophysiology care.

Balloon aortic valvuloplasty (BAV) has experienced a complex evolution in clinical practice, transitioning from an early therapeutic innovation to limited use, and more recently to a redefined role in the era of transcatheter aortic valve implantation (TAVI). In the first of our new practice pearls series, In Rhythm, Dr Gustavo Samaja (Sanatorio Colegiales, Buenos Aires, Argentina) shares practical insights into the contemporary role of BAV, including patient selection, procedural strategies, and its use as both a bridge and a decision-making tool. He also discusses how evolving healthcare systems and resource considerations continue to shape the balance between BAV and TAVI in everyday clinical practice.

Cardiovascular medicine in 2025 has been marked by rapid innovation and meaningful shifts in clinical practice. In this year-in-review, touchCARDIO brings together expert reflections highlighting paradigm-changing trial data, the emergence of pulsed field ablation and conduction system pacing, advances in imaging and prevention, and the accelerating integration of artificial intelligence. Collectively, these perspectives underscore a field evolving toward more precise, technology-enabled and preventive cardiovascular care, while emphasising the need to translate scientific progress into improved outcomes for patients worldwide.

As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchCARDIO. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the cardiology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year.